Related Experiment Video
Updated: Jun 18, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Papillomavirus prophylactic vaccines: established successes, new approaches
M Saveria Campo1, Richard B S Roden
1Division of Pathological Sciences, Institute of Comparative Medicine, Garscube Campus, University of Glasgow, Glasgow G61 1QH, United Kingdom. s.campo@vet.gla.ac.uk
Abstract:
Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Smallpox
Respiratory Syncytial Virus Disease
Microorganisms in Medicine and Therapeutics
Vaccinations
Poliomyelitis
